Vivitrol naltrexone: Phase IIIb start

This quarter, Alkermes will begin an open-label Phase IIIb trial (ALK21-021) to evaluate 380 mg of intramuscular Vivitrol given once monthly in combination with psychosocial support for 24 months in a...